SCHEMBL730697

SCHEMBL730697

CCOc1cc(C(=O)N2CCC3(CC2)CC(=O)c2cc(N4CCN(C(C)=O)CC4)ccc2O3)cc(OC)c1-c1cnn(C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 6/20 0.47
ALDH1A1 P00352 7/20 0.45
KDM4E B2RXH2 6/20 0.45
GAA P10253 5/20 0.45
HPGD P15428 4/20 0.45
CASP1 P29466 3/20 0.45
HSD17B10 Q99714 3/20 0.45
GLA P06280 5/20 0.45
CASP7 P55210 2/20 0.45
CYP1A2 P05177 1/20 0.45
KMT2A Q03164 1/20 0.45
THRB P10828 1/20 0.44
ACACA Q13085 1/20 0.44
HDAC3 O15379 3/20 0.43
HDAC4 P56524 3/20 0.43
HDAC1 Q13547 3/20 0.43
HDAC7 Q8WUI4 3/20 0.43
HDAC2 Q92769 3/20 0.43
HDAC10 Q969S8 3/20 0.43
HDAC11 Q96DB2 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL731131 0.92 ACACB (0.47) ACACBKMT2AACACAHDAC3HDAC4
SCHEMBL731132 0.91 ACACB (0.46) ACACBKMT2AACACAHDAC3HDAC4
SCHEMBL730528 0.89 ACACB (0.52) ACACBKMT2AACACA
SCHEMBL4417682 0.85 ACACB (0.49) ACACBKMT2AACACAHDAC3HDAC4
SCHEMBL742140 0.85 ACACB (0.49) ACACBALDH1A1KDM4EGAAHPGD
SCHEMBL741079 0.84 ACACB (0.53) ACACBACACAHDAC3HDAC4HDAC1
SCHEMBL730518 0.84 ACACB (0.47) ACACBKMT2AACACAHDAC3HDAC4
SCHEMBL4420767 0.84 ACACB (0.48) ACACBKMT2AACACA
SCHEMBL731214 0.84 ACACB (0.53) ACACBACACAHDAC3HDAC4HDAC1
SCHEMBL733394 0.84 ACACB (0.63) ACACBKMT2AACACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP claimed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US claimed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US claimed
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 ACACB 77/4885ALDH1A1 113/4885KDM4E 3445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.